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Abstract
Background: In 2005, the first disease-specific Helicobacter pylori virulence factor that induced duodenal ulcer and
had a suppressive action on gastric cancer has been identified, and was named duodenal ulcer promoting gene
(dupA). However, the importance of the dupA gene on clinical outcomes is conflicting in subsequent studies. The
aim of this study was to estimate the magnitude of the risk for clinical outcomes associated with dupA gene.
Methods: A meta-analysis of case-control studies which provided raw data on the infection rates with the dupA-
positive H. pylori detected by polymerase chain reaction was performed.
Results: Seventeen studies with a total of 2,466 patients were identified in the search. Infection with the dupA-
positive H. pylori increased the risk for duodenal ulcer by 1.41-fold (95% confidence interval [CI], 1.12-1.76) overall.
Subgroup analysis showed that the summary odds ratio (OR) was 1.57 (95% CI, 1.19-2.06) in Asian countries and
1.09 (95% CI, 0.73-1.62) in Western countries. There was no association between the presence of the dupA gene
and gastric cancer and gastric ulcer. Publication bias did not exist.
Conclusion: Our meta-analysis confirmed the importance of the presence of the dupA gene for duodenal ulcer,
especially in Asian countries.
Background
Helicobacter pylori (H. pylori) infection is now accepted
as the major cause of chronic gastritis. Several epide-
miological studies have shown that H. pylori infection is
also linked to the severe gastritis-associated diseases,
including peptic ulcer and gastric cancer (GC) [1]. In
1994, the International Agency for Research on Cancer
categorized H. pylori infection as a definite group I car-
cinogen [2]. The infection remains latent in the majority
of infected patients, with only approximately 20% of
infected individuals developing severe diseases. One pos-
sible reason for the varying outcomes of H. pylori infec-
tion relates to differences in the virulence of H. pylori
strains in addition to host, environmental, and dietary
factors.
Several H. pylori virulence factors associated with pep-
tic ulcer and GC have been reported, including cagA,
vacA, babA and oipA [1,3-6]. Lu et al. [7] described a
novel virulence factor, duodenal ulcer promoting gene
(dupA), which encompassed both jhp0917 and jhp0918
located in the plasticity region of the H. pylori genome.
Interestingly, the dupA gene is homologous to virB4, a
gene encoding a component protein of the type IV secre-
tion system (TFSS) in Agrobacterium tumefaciens. They
reported that infections with dupA-positive strains
increased the risk for duodenal ulcer (DU) but were pro-
tective against gastric atrophy, intestinal metaplasia and
GC in the Japanese, Korean and Columbian subjects.
Intriguingly, dupA is the first genetic factor of H. pylori
to be associated with differential susceptibility to DU and
GC, and thus it could be considered as a disease specific
virulence marker. The pathogenic mechanism of dupA
appears to involve the induction of interleukin (IL)-8
production in the antrum, leading to antrum-predomi-
nant gastritis, a well-recognized characteristic of DU [7].
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However, the role of dupA was controversial subse-
quently since several studies were unable to reproduce
the observation in other population including Japan
[8-12]. Although Hussein recently reported the systema-
tic review which proved the high prevalence of dupA-
positive H. pylori in patients with DU [13], he determined
the conclusion based on simple combined data but not
meta-analysis (e.g., he did not show the meta-analysis
model, heterogeneity, publication bias). In this study, we
aimed to examine the relationship between the dupA
gene and clinical outcomes based on the method of
meta-analysis.
Methods
A literature search was performed using the PubMed
databases for articles published through August 2010,
using the following text words: 1) dupA, and 2) pylori
or Helicobacter. We did not include abstract alone or
unpublished articles.
Inclusion Criteria
The following criteria were applied to select fully pub-
lished case-control studies examining the relationship
between the dupA gene and clinical outcomes (gastritis,
gastric ulcer [GU], DU, and GC) in adult population; the
presence of dupA gene was examined by polymerase
chain reaction (PCR), or PCR plus dot blot; original arti-
cles published in English. Studies were excluded if raw
data were not presented. When it appeared that the same
subjects were presented in multiple reports, the earliest
paper was selected. All potentially relevant articles were
reviewed by two investigators (S.S and Y.Y) indepen-
dently and disagreement was resolved by discussion.
Data Extraction
Data were extracted from each study by investigators
independently and entered into a computerized database.
The information retrieved covered countries where the
study was performed, characteristics of cases and con-
trols, method for detection of the dupA gene, number of
subjects, the dupA status according to clinical outcomes.
Three studies examined the prevalence of the dupA gene
in several countries [7,8,11], thus these data in each
country was entered in separate sheet as an independent
study.
Statistical analysis
Summary odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated from the raw data. The Mantel-
Haenszel method was used to test for statistical heteroge-
neity. When statistical heterogeneity was noted, the
proportion of the total heterogeneity variance was cal-
culated using a fixed-effects model from each study
to guide the search for sources of methodologic and
clinically important variables. To exclude any possible
influence of a single study, we performed a sensitivity
analysis to evaluate whether the exclusion of any single
study substantial altered the magnitude or statistical
result of the summary estimate. Publication bias was
assessed by funnel plots and regression test by Egger
et al [14]. P value of < 0.05 was considered as statistically
significant in all meta-analyses. All analyses were per-
formed using Comprehensive Meta-analysis software
(version 2, Biostat, Englewood, NJ).
Results
The literature searches generated 17 potentially relevant
citations. Of these, six articles were excluded (3 were
review articles [13,15,16], one was not case-control study
[17], one was in vitro study [18], and one was following
study [19]), therefore 11 articles met the inclusion cri-
teria. Three articles included several countries (three in
Lu et al, four in Argent et al, and two in Schmidt et al).
Although Schmidt et al. examined the dupA status in five
countries [11], data from only two countries was case-
control. In this study, data from different countries in
one article was considered as separate studies (data);
therefore, seventeen studies with a total of 2,466 patients
met the inclusion criteria (Table 1). Among these studies,
there was no age- and sex-matched case-control study.
The dupA status was evaluated by PCR technique except
two studies which performed PCR and dot blot technique
[12,20]. Multiple primer pairs were used in 11 studies
[8,10-12,20-22]. The dupA status in seven studies was
determined based on the presence both of jhp0917 and
jhp0918 (dupA-positive only if both jhp0917 and jhp0918
were positive) [7,9,22-24].
The association between the dupA status and
duodenal ulcer
The prevalence of the dupA gene in DU patients was
examined in 17 studies from 13 countries (Figure 1).
The prevalence of the dupA gene ranged from 18.2% to
92.3% in DU patients and 6.7% to 92.4% in controls.
Among 17 studies, significantly higher prevalence of the
dupA gene in DU compared with control was found in
five studies [7,11,20,21].
The overall prevalence of the dupA gene was 49.5%
(376 of 759) in DU and 42.5% (408 of 960) in controls,
yielding an estimate OR of 1.33 (95% CI, 1.09-1.60).
Summary OR in fixed-effect model was 1.41 (95% CI,
1.12-1.76). However, the test of heterogeneity was signif-
icant among these studies (Q = 28.15 with d.f. = 16, p =
0.03), suggesting the existence of either methodologic or
clinical heterogeneity. By exploring the sources of het-
erogeneity, we found that the study by Gomes et al. [10]
showed the larger differential in the prevalence of the
dupA gene compared with other studies. They reported
Shiota et al. Gut Pathogens 2010, 2:13
http://www.gutpathogens.com/content/2/1/13
Page 2 of 6
the prevalence of the dupA gene was 87.3% in DU and
92.4% in control. In addition, the study by Lu et al. in
Korea showed the lower prevalence of the dupA gene
especially in control (6.7%) [7]. Sensitivity analysis
excluding these 2 studies showed a similar OR of 1.46
with a 95% CI of 1.15-1.85 and the test of heterogeneity
was no longer statistically significant (Q = 18.05 with d.
f. = 14, p = 0.20). Publication bias did not exist (inter-
cept, 1.28; p = 0.17).
Subgroup analysis was also performed by two areas
(Asian or Western countries). The study in South Africa
[8] was not included in both. The prevalence of the
dupA gene was 37.9% (183 of 483) in DU and 29.2%
(180 of 616) in controls in Asian countries. It was 68.8%
(181 of 263) in DU and 66.0% (217 of 329) in controls
in Western countries. Summary OR was 1.57 (95% CI,
1.19-2.06) in Asian countries and 1.09 (95% CI, 0.73-
1.62) in Western countries. When the study by Gomes
et al. was excluded, it was 51.8% (71 of 137) in DU and
45.4% (84 of 185) in controls in Western countries
(OR = 1.34 with a 95% CI, 0.85-2.13).
The association between the dupA status and
gastric cancer
The prevalence of the dupA gene in GC patients was
examined from 12 studies from 9 countries (Figure 2).
The prevalence ranged from 6.0% to 100% in GC
patients and 6.7% to 92.4% in controls. Among 12 stu-
dies, significantly higher prevalence in GC compared
with control was found in two studies [7,11].
The overall prevalence of the dupA gene was 41.7%
(184 of 441) in GC and 46.8% (336 of 718) in controls,
yielding an estimate OR of 0.80 (95% CI, 0.63-1.02).
Summary OR in fixed-effect model was 0.88 (95% CI,
0.66-1.17). However, significant heterogeneity existed
Table 1 List of studies included in the meta-analysis
Gastritis Duodenal ulcer Gastric ulcer Gastric cancer
Authors Country Reference Positive all positive all positive all positive all
Lu Japan 7 7 50 14.0% 11 30 36.7% 13 50 26.0% 3 30 10.0%
Lu Korea 7 2 30 6.7% 24 65 36.9% 5 30 16.7% 3 50 6.0%
Lu Colombia 7 15 40 37.5% 22 45 48.9% 12 30 40.0% 6 50 12.0%
Arachchi India 20 16 70 22.9% 36 96 37.5%
Argent South Africa 8 11 15 73.3% 12 13 92.3% 16 18 88.9%
Argent Belgium 8 29 76 38.2% 20 40 50.0% 10 19 52.6%
Argent USA 8 9 20 45.0% 9 21 42.9% 2 3 66.7%
Argent China 8 3 12 25.0% 2 11 18.2% 2 5 40.0% 1 1 100.0%
Douraghi Iran 9 34 68 50.0% 15 30 50.0% 9 23 39.1% 20 36 55.6%
Gomes Brazil 10 133 144 92.4% 110 126 87.3% 71 81 87.7%
Hussein Iraq 21 5 29 17.2% 9 15 60.0% 2 5 40.0%
Pacheco Brazil 23 18 29 62.1% 13 20 65.0% 14 24 58.3%
Zhang China 24 51 133 38.3% 46 101 45.5% 11 47 23.4% 19 79 24.1%
Schmidt Sweden 11 13 20 65.0% 7 11 63.6% 13 21 61.9%
Schmidt China 11 15 52 28.8% 10 16 62.5% 12 22 54.5%
Nguyen Japan 12 23 78 29.5% 17 62 27.4% 17 59 28.8% 10 34 29.4%
Yeh Taiwan 22 24 94 25.5% 13 57 22.8% 6 30 20.0%
Figure 1 The results of meta-analysis for the risk of duodenal
ulcer in dupA-positive H. pylori infection. Odds ratios (ORs) and
their 95% confidence intervals (CI) in summary and for each study
are presented with weighting in a fixed-effect model.
Figure 2 The results of meta-analysis for the risk of gastric
cancer in dupA-positive H. pylori infection.
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among these studies (Q = 21.44 with d.f. = 12, p = 0.04).
The study in Colombia by Lu et al. [7] showed the larger
differential in the prevalence of the dupA gene when
compared with other studies. They reported the preva-
lence of the dupA gene was 6.0% in GC and 6.7% in con-
trol. Sensitivity analysis excluding this study showed a
similar OR of 0.98 with a 95% CI of 0.72-1.32 with no
heterogeneity (Q = 14.73 with d.f. = 11, p = 0.19).
Subgroup analysis also did not show the significant
association between GC and dupA both in Asian and
Western countries. The prevalence of the dupA gene
was 27.0% (68 of 252) in GC and 31.9% (135 of 423) in
controls in Asian countries. The prevalence was 58.5%
(100 of 171) in GC and 67.9% (190 of 380) in controls
in Western countries.
The association between the dupA status and gastric ulcer
The prevalence of the dupA gene in gastric ulcer (GU)
patients was examined from 11 studies from 9 countries
(Figure 3). The prevalence ranged from 16.7 to 66.7% in
GU patients and 6.7 to 62.1% in controls. Among 11
studies, no study showed the significantly higher preva-
lence in GU compared with control.
The overall prevalence of the dupA gene was 30.3% (93
of 306) in GU and 32.7% (191 of 583) in controls, yielding
an estimate OR of 0.90 (95% CI, 0.66-1.20). Summary OR
in fixed-effect model was 0.95 (95% CI, 0.68-1.32) with no
heterogeneity (Q = 10.25 with d.f. = 10, p = 0.41). Sub-
group analysis also did not show the significant association
between GC and the dupA status both in Asian and
Western countries. The prevalence of the dupA gene was
26.1% (65 of 249) in GU and 30.2% (149 of 494) in con-
trols in Asian countries. The prevalence was 49.1% (28 of
57) in GC and 47.2% (42 of 89) in controls in Western
countries.
The difference of prevalence in Asian and
Western countries
The overall prevalence of the dupA gene was 31.0% (496
of 1,600) in Asian countries and 64.1% (526 of 820)
in Western countries. It was significantly higher in
Western countries than Asian countries (p < 0.0001).
When the study by Gomes et al. was excluded, this
trend did not change (p < 0.0001).
Discussion
Our present meta-analysis shows that the presence of the
dupA gene was significantly associated with DU.
Although several studies failed to show the positive asso-
ciation between the dupA status and clinical outcomes,
the meta-analysis confirmed the original report in 2005
[7]. Especially, the presence of the dupA gene was asso-
ciated with DU in Asian countries; however it was not in
Western countries. This difference may be due to the dif-
ferent prevalence of the dupA gene between Asian and
Western countries. Furthermore, the study by Gomes et
al. was the resource of heterogeneity due to larger differ-
ence compared with other studies. This mean the simple
combined calculation such as the report by Hussein [13]
is not strictly accurate to concluded although the trend
was not changed. In addition, we found that the several
miscount exist in the report by Hussein (e.g., he counted
the mean age but not the number of subjects from the
study Zhang et al. [24] and mistook the calculation from
the study by Pacheco et al. [23]).
When Argent et al. combined Belgian and South African
populations, the presence of the dupA gene was signifi-
cantly associated with the presence of GC. There was also
a non-significant trend towards an association between
the dupA gene and DU in the combined Belgian and
South African population. However, we did not include
the South Africa in Western countries. It is not relevant to
combine random populations since it is unclear whether
the South African strains were taken from patients of
European descent and recent studies confirmed that the
genomic structures of some South African strains (i.e.,
HpAfrica2 type) were relatively different from those from
the European population (i.e., HpEurope type) [25,26].
In a study examining strains from Brazilian children
and adults, the prevalence of the dupA gene was extre-
mely high (92%; 445/482) irrespective of clinical out-
comes [10]. Interestingly, the frequency of the dupA
gene was significantly higher in strains from children
than in those from adults. H. pylori infection is typically
acquired in childhood and persists throughout life
unless treated with a combination of anti-acid and anti-
microbial therapy, so it is speculated that the dupA gene
might be lost during long-term infections in which the
gastric mucosa gradually develop chronic atrophic gas-
tritis and GC. Therefore, their results might partially
support the original hypothesis that the dupA gene is a
marker associated with gastric damage that leads to the
development of gastric cancer. Therefore, we need to
pay attention to the age of each disease in case-control
study. For example, mean age of DU was younger than
Figure 3 The results of meta-analysis for the risk of gastric
ulcer in dupA-positive H. pylori infection.
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that of gastritis in the study by Zhang et al. (41 years
old in DU vs 59 years old in gastritis) [24]. Case-control
study matched age- and sex- should be performed in
the future.
Overall, there are distinct geographical variations in the
prevalence of the dupA gene, and there appears to be an
association between dupA and DU in some populations
but not in others. As Argent et al. [8] reported, the asso-
ciation of dupA with DU in only some populations could
reflect differences in the definition or diagnosis of ulcers
or in the use of drugs that either cause or heal ulcers in
these populations. In addition, the discrepancy could be
related to the limitation of PCR techniques for detecting
the intact dupA gene. In some studies, only one set
of primer pairs for jhp0917 and jhp0918 was used
[7,9,23,24]: use of multiple primer pairs is recommended
for detection of the dupA gene in future studies. None of
the previous reports considered the frameshift mutation
after position 1385 as a criterion for the presence of the
dupA gene [7,10]. More importantly, Gomes et al.
reported frameshift mutations in 14/86 (16%) dupA-posi-
tive sequenced samples [10]; a single adenine insertion
after position 1426 of dupA or at position 2998 of the
jhp0917-jhp0918 gene of the J99 strain that created a pre-
mature stop codon and may have considerable effects on
protein expression or function. In their study, they
counted the truncated samples as dupA-positive; how-
ever, it is clear that these mutated sequences would not
produce intact DupA protein. For example, the expres-
sion of the blood group antigen binding adhesin (BabA)
protein does not always correlated with the babA gene
expression [27]. It will be better to detect intact dupA by
measuring intact DupA protein using immunoblotting
techniques, which has not been reported previously. In
addition, the vir genes exist before and after the region of
the dupA locus [16]. In the strain Shi470, for example,
virB2, virB3, virB4 (dupA), virB8, virB9, virB10, virB11,
virD4, and virD2 were detected. These are structurally
similar to the type IV secretion system (T4SS) called cag
PAI and ComB and thought to be the third T4SS.
Recently, T4SS containing dupA was named as tfs3a, and
T4SS having virB4 sequence, but not dupA was named as
tfs3b [28]. These observations suggest that only strains
that are intact dupA-positive and form a novel type IV
secretion system might be involved in gastroduodenal
diseases. If this is true, examining the presence of DupA/
dupA alone might not be sufficient. Study on DupA is
still in their early stages, and great progress is expected in
the near future.
Conclusions
Infection with the dupA-positive H. pylori increased the
risk for DU overall and this evidence was significant in
Asian countries. In contrast, the relationship between
dupA and GC and GU was not clear from the meta-ana-
lysis. Case-control study matched age- and sex- should
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